An angiotensin II antagonist, [sacrosine1, isoleucine8] angiotensin II, was infused into thyrotoxic patients. Blood pressure was monitored before and during the infusions to investigate whether the renin-angiotensin-aldosterone system was involved in the maintenance of blood pressure in normotensive and hypertensive thyrotoxic patients.
Plasma renin activity (PRA) has been reported to be elevated in patients with hyperthyroidism (Hauger-Klevene et al., 1972; . This abnormality may be attributed to an increased sensitivity of the renin secretory mechanism to adrenergic stimuli (Hauger-Klevene et al., 1972; .
Systolic hypertension is often observed in hyperthyroidism.
The high cardiac output induced by elevated serum thyroid hormone concentrations may be the major cause of the hypertension because this hormone has an inotropic positive action on the myocardium and enhances its sensitivity to catecholamine. (Strong et al., 1977) .
In this study one of the commercially available angiotensin II antagonists, [sarcosine1, isoleucin8] angiotensin II ([Sar1, Ile8] ANGII), was infused into thyrotoxic patients with and without hypertension and blood pressure was monitored to investigate whether increased activity of the renin-angiotensin-aldosterone system was involved in the maintenance of their blood pressure. Mean levels of T4, T3, PRA and PAC in the normotensive responders were significantly higher than those in normotensive non-responders (Table1).
There was no significant differences in the laboratory values between hypertensive and normotensive non-responders except that T3 levels were significantly higher in the hypertensive patients.
OGIHARA et al. (Brunner et al., 1974; Davis et al., 1974) , and also to increase our understanding of the role of the renin-angiotensin system in the maintenance of blood pressure in sodium depleted normal subjects (Haber, 1976; Noth et al., 1977) , as well as in patients with secondary aldosteronism such as Bartter's syndrome (Yamamoto et al., 1976; Kono et al., 1976) and liver cirrhosis with ascites (Schroeder et al., 1976; Hata et al., 1979) . Blood pressure reduction by angiotensin II antagonist is interpreted as indicating that the blood pressure is maintained in part by increased renin-angiotensin activity.
It is known that the pretreatment of sodium depletion is necessary to increase the antagonistic activity and decrease the agonistic pressor action of [Sar1, Ile8] ANGII . In this study furosemide was given prior to the infusion of About one third of our normotensive patients with hyperthyroidism had depressor responses to infusion of an angiotensin II antagonist, while the blood pressure of the hyperthyroid patients with systolic hypertension were little changed. Blood pressure reduction observed in the responders is not attributed to and difference in diuresis following furosemide administration because there was no significant difference in body weight change due to furosemide between the groups. Serum T4, T3, PRA and PAC in patients with depressor responses to the antagonist were significantly higher than in non-responders. Presumably most patients with severe hyperthyroidism had increased activity of their renin-angiotensin-aldosterone system which was involved in the maintenance of their blood pressure. Blood pressure reduction in response to the antagonist was not seen in any patients after euthyroidism was achieved following medical treatment.
The eight hyperthyroid patients with systolic hypertension in the present study had mean values of PRA and PAC similar to those of the normotensive non-responsers and had no reduction in blood pressure due to the angiotensin II antagonist. These results suggest that increased activity of the reninangiotensin-aldosterone system did not contribute to their systolic hypertension.
It had earlier been reported that patients with hyperthyroidism have increased PRA (Hauger-Klevene et al., 1972; . The PRA elevations observed in the present study are consistent with those reports.
In an acute experiment, Shahawy et al.,(1971) produced elevated PRA and elevated aldosterone excretion rates in dogs by thyroxine administration. It has been proposed that increased activity of the juxtaglomerular apparatus in response to autonomic stimulation in hyperthyroidism is a major cause of the incrreased renin secretion.
The high PRA in thyrotoxic patients can be suppressed by propranolol (Hauger-Klevene et al., 1972; . Hauger-Klevene et al.(1972) have shown that the pressor response to exogeneous angiotensin II is blunted in thyrotoxic patients. This may account for the normal blood pressure of some hyperthyroid patients with increased PRA (Hauger-Klevene et al., 1972) . Plasma volumes were not measured in this study. Patients with severe thyrotoxicosis might have volume depletion. Thyroid hormone has some diuretic effects (Bradley, 1971) . The increased perspiration of the patients with severe hyperthyroidism might deplete the extracellular fluid volume. Both increased and decreased plasma volumes have been reported in hyperthyroid patients (Danowski, 1971) . In severe thyrotoxic patients increased activity of the reninangiotensin-aldosterone system might be a compensatory mechanism for the maintenance of normal blood pressure. Simultaneous measurement of circulating plasma volume and re-examination of the response to the infusion of angiotensin II antagonints after volume repletion may clarify this problem.
